2 results
Approved WMORecruitment stopped
JNJ-2607019 is an investigational drug being developed for gastroesophageal reflux disease (GERD) to reduce the complaints of abdominal pain and heartburn in people with this disease. JNJ-26070109 inhibits the gastrin receptor in the stomach. The…
Approved WMOCompleted
The objectives of Part B of the study are as follows: Primary: To assess the safety and tolerability of CALY-002 following multiple ascending doses administered IV in subjects with coeliac disease (CeD). Secondary: (1) To characterise the PK of CALY…